Skip to Content

Canakinumab Dosage

Medically reviewed by Drugs.com. Last updated on July 24, 2020.

Applies to the following strengths: 150 mg; 150 mg/mL

Usual Adult Dose for Familial Cold Autoinflammatory Syndrome

15 kg less than or equal to 40 kg: 2 mg/kg subcutaneously every 8 weeks
Greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and muckle-wells syndrome (MWS)

Usual Adult Dose for Muckle Wells Snydrome

15 kg less than or equal to 40 kg: 2 mg/kg subcutaneously every 8 weeks
Greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and muckle-wells syndrome (MWS)

Usual Adult Dose for Cryopyrin-Associated Periodic Syndrome

15 kg less than or equal to 40 kg: 2 mg/kg subcutaneously every 8 weeks
Greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and muckle-wells syndrome (MWS)

Usual Adult Dose for Familial Mediterranean Fever

Up to 40 kg: 2 mg/kg subcutaneously every 4 weeks; dose can be increased to 4 mg/kg subcutaneously every 4 weeks if response is not adequate
Greater than 40 kg: 150 mg subcutaneously every 4 weeks; dose can be increased to 300 mg subcutaneously every 4 weeks if response is not adequate

Uses: For autoinflammatory periodic fever syndromes including periodic tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF)

Usual Adult Dose for Hyperimmunoglobulin D Periodic Fever Syndrome

Up to 40 kg: 2 mg/kg subcutaneously every 4 weeks; dose can be increased to 4 mg/kg subcutaneously every 4 weeks if response is not adequate
Greater than 40 kg: 150 mg subcutaneously every 4 weeks; dose can be increased to 300 mg subcutaneously every 4 weeks if response is not adequate

Uses: For autoinflammatory periodic fever syndromes including periodic tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF)

Usual Adult Dose for Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome

Up to 40 kg: 2 mg/kg subcutaneously every 4 weeks; dose can be increased to 4 mg/kg subcutaneously every 4 weeks if response is not adequate
Greater than 40 kg: 150 mg subcutaneously every 4 weeks; dose can be increased to 300 mg subcutaneously every 4 weeks if response is not adequate

Uses: For autoinflammatory periodic fever syndromes including periodic tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF)

Usual Adult Dose for Still's Disease

7.5 kg or greater: 4 mg/kg (maximum 300 mg) subcutaneously every 4 weeks

Use: Still's Disease, including Adult-Onset Still's Disease (AOSD)

Usual Pediatric Dose for Familial Cold Autoinflammatory Syndrome

4 years and older:
-Weight 15 kg to less than or equal to 40 kg: 2 mg/kg subcutaneously every 8 weeks; for children 15 to 40 kg with an inadequate response, the dose can be increased to 3 mg/kg subcutaneously every 8 weeks
-Weight greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and muckle-wells syndrome (MWS) in children 4 years and older

Usual Pediatric Dose for Muckle Wells Snydrome

4 years and older:
-Weight 15 kg to less than or equal to 40 kg: 2 mg/kg subcutaneously every 8 weeks; for children 15 to 40 kg with an inadequate response, the dose can be increased to 3 mg/kg subcutaneously every 8 weeks
-Weight greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and muckle-wells syndrome (MWS) in children 4 years and older

Usual Pediatric Dose for Cryopyrin-Associated Periodic Syndrome

4 years and older:
-Weight 15 kg to less than or equal to 40 kg: 2 mg/kg subcutaneously every 8 weeks; for children 15 to 40 kg with an inadequate response, the dose can be increased to 3 mg/kg subcutaneously every 8 weeks
-Weight greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and muckle-wells syndrome (MWS) in children 4 years and older

Usual Pediatric Dose for Familial Mediterranean Fever

2 years and older:
-Weight 40 kg or less: 2 mg/kg subcutaneously every 4 weeks; can increase to 4 mg/kg subcutaneously every 4 weeks if response is inadequate
-Weight greater than 40 kg: 150 mg subcutaneously every 4 weeks; can increase to 300 mg subcutaneously every 4 weeks if response is inadequate

Use: For the treatment of autoinflammatory periodic fever syndromes including TRAPS, HIDS/MKD, and FMF in pediatric patients 2 years and older

Usual Pediatric Dose for Hyperimmunoglobulin D Periodic Fever Syndrome

2 years and older:
-Weight 40 kg or less: 2 mg/kg subcutaneously every 4 weeks; can increase to 4 mg/kg subcutaneously every 4 weeks if response is inadequate
-Weight greater than 40 kg: 150 mg subcutaneously every 4 weeks; can increase to 300 mg subcutaneously every 4 weeks if response is inadequate

Use: For the treatment of autoinflammatory periodic fever syndromes including TRAPS, HIDS/MKD, and FMF in pediatric patients 2 years and older

Usual Pediatric Dose for Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome

2 years and older:
-Weight 40 kg or less: 2 mg/kg subcutaneously every 4 weeks; can increase to 4 mg/kg subcutaneously every 4 weeks if response is inadequate
-Weight greater than 40 kg: 150 mg subcutaneously every 4 weeks; can increase to 300 mg subcutaneously every 4 weeks if response is inadequate

Use: For the treatment of autoinflammatory periodic fever syndromes including TRAPS, HIDS/MKD, and FMF in pediatric patients 2 years and older

Usual Pediatric Dose for Juvenile Idiopathic Arthritis

2 years and older:
7.5 kg or greater: 4 mg/kg (maximum 300 mg) subcutaneously every 4 weeks

Use: For the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years and older and 7.5 kg or more

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 4 years with CAPS.
Safety and efficacy have not been established in patients younger than 2 years with TRAPS, HIDS/MKD, FMF.
Safety and efficacy have not been established in patients younger than 2 years or weighing less than 7.5 kg with SJIA.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Avoid injection into scar tissue.
-Vials are intended for single use in 1 patient; discard any unused portion.

Storage requirements:
-The unopened vial should be refrigerated 2C to 8C (36F to 46 F). Do not freeze.
-Store in the original carton to protect from light.
-Do not use beyond the date stamped on the label.
-This drug does not contain preservatives.

General:
-Do not use beyond the date stamped on the label.
-This drug does not contain preservatives.
-Discard any unused portion or waste material in accordance with local requirements.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.